ARVN News and Press, Arvinas Inc. From 05/02/23

Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial PR Newswire NEW HAVEN, Conn. and SAN FRANCISCO , May 2, 2023 /PRNewswire/ -- Arvinas, Inc. (Nasdaq:...

NEW HAVEN, Conn., April 21, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, and Sean Cassidy, Chief Financial Office...

NEW HAVEN, Conn., April 03, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Kelly Page has joined the company as Senior Vice President, Global Head of Oncology S...

2023-03-29 16:17:06 ET Summary Arvinas' PROTAC approach has several advantages over conventional drugs, including the potential to target "undruggable" proteins, achieve tissue-specific targeting, and cross the blood-brain barrier. The company has three lead products in clinical t...

2023-03-21 09:28:28 ET Ventyx Biosciences ( NASDAQ: VTYX ) traded higher pre-market Tuesday after Wells Fargo initiated its coverage with an Overweight recommendation citing an attractive entry point ahead of multiple catalysts over the next 12 – 18 months. The comp...

2023-03-18 01:44:45 ET Summary The first and original spin on stock market investing meshed with the thrill of the NCAA March Madness tournament! Which "team" (Asset Class) wins out the rest of 2023? Will active or passive be the answer? March Madness is back! No...

Arvinas press release ( NASDAQ: ARVN ): Q4 GAAP EPS of -$1.56 misses by $0.39 . Revenue of $38M (+32.4% Y/Y) beats by $2.68M . For further details see: Arvinas GAAP EPS of -$1.56 misses by $0.39, revenue of $38M beats by $2.68M

– Initiated multiple trials with ARV-471, including a 2L+ Phase 3 trial for patients with metastatic breast cancer – – Presented Phase 2 monotherapy expansion data from the VERITAC trial for the treatment of patients with metastatic or locally advanced ER+/HER...

NEW HAVEN, Conn., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences: Guggenhe...

Summary Kymera Therapeutics, Inc.'s KT-474 HS/AD data de-risked the IRAK4 protein degradation platform, as did Sanofi's partnering. However, more differentiating data seems to be needed in these indications and with IRAK4 inhibitors. I also wish to see more data from self-owned prod...